{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T07:35:21Z","timestamp":1794641721995,"version":"4.9.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U23A20390"],"award-info":[{"award-number":["U23A20390"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004479","name":"Natural Science Foundation of Jiangxi Province","doi-asserted-by":"publisher","award":["20224ACB206007"],"award-info":[{"award-number":["20224ACB206007"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004479","name":"Natural Science Foundation of Jiangxi Province","doi-asserted-by":"publisher","award":["2024A1515010331"],"award-info":[{"award-number":["2024A1515010331"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2023A1515010321"],"award-info":[{"award-number":["2023A1515010321"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Discov."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Enzalutamide resistance is a dynamic process often culminating in the aggressive progression to neuroendocrine prostate cancer (NEPC). This lineage plasticity is hypothesized to be driven by underlying epigenetic alterations, yet the core molecular drivers remain unclear. Elucidating these factors is of significant clinical importance for overcoming resistance. To model this transition, we established a dynamic gradient-resistant cell model simulating the clinical response to enzalutamide, and found robust upregulation of the chromatin remodeling factor SMARCA4 in resistant cells. Both in vitro and in vivo experimental results demonstrated that inhibiting SMARCA4 effectively suppresses tumor progression and reverses neuroendocrine transformation. Mechanistically, integrated multi-omics analysis, correlation studies, and protein interaction experiments revealed the transcription factor PROX1 as a crucial downstream target of SMARCA4, where its inhibition alone was sufficient to reverse the aggressive malignancy and neuroendocrine characteristics of resistant cells. We further demonstrated that SMARCA4 enhances H3K27ac levels and chromatin accessibility at the PROX1 locus to regulate its expression. Importantly, the tumor-suppressive effect of SMARCA4 knockdown could be rescued by histone deacetylase inhibitors (HDACi), achieving a level of recovery comparable to PROX1 overexpression. In summary, this study defines a core epigenetic pathway, showing that increased SMARCA4 activity promotes luminal-to-neuroendocrine transformation by enhancing histone acetylation and chromatin accessibility at the PROX1 locus. Targeting the SMARCA4-PROX1 axis provides a valuable therapeutic strategy for combating enzalutamide resistance and NEPC progression.<\/jats:p>","DOI":"10.1038\/s41420-026-03068-0","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T16:35:05Z","timestamp":1774456505000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["SMARCA4 promotes lineage plasticity and enzalutamide resistance in prostate cancer by regulating PROX1 via H3K27 acetylation"],"prefix":"10.1038","volume":"12","author":[{"given":"Chenwei","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayao","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaojian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yadong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanpeng","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4641-3412","authenticated-orcid":false,"given":"Yifan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shidong","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5925-6922","authenticated-orcid":false,"given":"Qiang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"key":"3068_CR1","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1001\/jamaoncol.2024.0591","volume":"10","author":"M Hussain","year":"2024","unstructured":"Hussain M, Fizazi K, Shore ND, Heidegger I, Smith MR, Tombal B, et al. Metastatic hormone-sensitive prostate cancer and combination treatment outcomes: a review. JAMA Oncol. 2024;10:807\u201320.","journal-title":"JAMA Oncol"},{"key":"3068_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nm.4341","volume":"23","author":"DS Rickman","year":"2017","unstructured":"Rickman DS, Beltran H, Demichelis F, Rubin MA. Biology and evolution of poorly differentiated neuroendocrine tumors. Nat Med. 2017;23:1\u201310.","journal-title":"Nat Med"},{"key":"3068_CR3","doi-asserted-by":"publisher","first-page":"6916","DOI":"10.1158\/1078-0432.CCR-19-1423","volume":"25","author":"H Beltran","year":"2019","unstructured":"Beltran H, Hruszkewycz A, Scher HI, Hildesheim J, Isaacs J, Yu EY, et al. The role of lineage plasticity in prostate cancer therapy resistance. Clin Cancer Res J Am Assoc Cancer Res. 2019;25:6916\u201324.","journal-title":"Clin Cancer Res J Am Assoc Cancer Res"},{"key":"3068_CR4","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1158\/0008-5472.CAN-23-0593","volume":"83","author":"A Lundberg","year":"2023","unstructured":"Lundberg A, Zhang M, Aggarwal R, Li H, Zhang L, Foye A, et al. The genomic and epigenomic landscape of double-negative metastatic prostate cancer. Cancer Res. 2023;83:2763\u201374.","journal-title":"Cancer Res"},{"key":"3068_CR5","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41571-020-0340-z","volume":"17","author":"\u00c1 Quintanal-Villalonga","year":"2020","unstructured":"Quintanal-Villalonga \u00c1, Chan JM, Yu HA, Pe\u2019er D, Sawyers CL, Sen T, et al. Lineage plasticity in cancer: A shared pathway of therapeutic resistance. Nat Rev Clin Oncol. 2020;17:360\u201371.","journal-title":"Nat Rev Clin Oncol"},{"key":"3068_CR6","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nm.4045","volume":"22","author":"H Beltran","year":"2016","unstructured":"Beltran H, Prandi D, Mosquera JM, Benelli M, Puca L, Cyrta J, et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med. 2016;22:298\u2013305.","journal-title":"Nat Med"},{"key":"3068_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36253-1","volume":"14","author":"G Chakraborty","year":"2023","unstructured":"Chakraborty G, Gupta K, Kyprianou N. Epigenetic mechanisms underlying subtype heterogeneity and tumor recurrence in prostate cancer. Nat Commun. 2023;14:567.","journal-title":"Nat Commun"},{"key":"3068_CR8","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.167440","volume":"8","author":"A Kumaraswamy","year":"2023","unstructured":"Kumaraswamy A, Duan Z, Flores D, Zhang C, Sehrawat A, Hu YM, et al. LSD1 promotes prostate cancer reprogramming by repressing TP53 signaling independently of its demethylase function. JCI Insight. 2023;8:e167440.","journal-title":"JCI Insight"},{"key":"3068_CR9","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adf6732","volume":"15","author":"Y Yamada","year":"2023","unstructured":"Yamada Y, Venkadakrishnan VB, Mizuno K, Bakht M, Ku SY, Garcia MM, et al. Targeting DNA methylation and B7-H3 in RB1-deficient and neuroendocrine prostate cancer. Sci Transl Med. 2023;15:eadf6732.","journal-title":"Sci Transl Med"},{"key":"3068_CR10","doi-asserted-by":"publisher","first-page":"224","DOI":"10.4103\/tcmj.tcmj_220_20","volume":"33","author":"WC Cheng","year":"2021","unstructured":"Cheng WC, Wang HJ. Current advances of targeting epigenetic modifications in neuroendocrine prostate cancer. Tzu Chi Med J. 2021;33:224\u201332.","journal-title":"Tzu Chi Med J"},{"key":"3068_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25260-9","volume":"12","author":"Y Xue","year":"2021","unstructured":"Xue Y, Morris JL, Yang K, Fu Z, Zhu X, Johnson F, et al. SMARCA4\/2 loss inhibits chemotherapy-induced apoptosis by restricting IP3R3-mediated Ca2+ flux to mitochondria. Nat Commun. 2021;12:5404.","journal-title":"Nat Commun"},{"key":"3068_CR12","first-page":"504","volume":"56","author":"AHK Cheung","year":"2024","unstructured":"Cheung AHK, Wong KY, Chau SL, Xie F, Mui Z, Li GYH, et al. SMARCA4 deficiency and mutations are frequent in large cell lung carcinoma and are prognostically significant. Pathol (Philos). 2024;56:504\u201315.","journal-title":"Pathol (Philos)"},{"key":"3068_CR13","doi-asserted-by":"publisher","first-page":"2956","DOI":"10.1111\/jcmm.16330","volume":"25","author":"Y Wang","year":"2021","unstructured":"Wang Y, Yang CH, Schultz AP, Sims MM, Miller DD, Pfeffer LM. Brahma-related gene-1 (BRG1) promotes the malignant phenotype of glioblastoma cells. J Cell Mol Med. 2021;25:2956\u201366.","journal-title":"J Cell Mol Med"},{"key":"3068_CR14","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/s41586-021-04246-z","volume":"601","author":"L Xiao","year":"2022","unstructured":"Xiao L, Parolia A, Qiao Y, Bawa P, Eyunni S, Mannan R, et al. Targeting SWI\/SNF ATPases in enhancer-addicted prostate cancer. Nature. 2022;601:434\u20139.","journal-title":"Nature"},{"key":"3068_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19328-1","volume":"11","author":"J Cyrta","year":"2020","unstructured":"Cyrta J, Augspach A, De Filippo MR, Prandi D, Thienger P, Benelli M, et al. Role of specialized composition of SWI\/SNF complexes in prostate cancer lineage plasticity. Nat Commun. 2020;11:5549.","journal-title":"Nat Commun"},{"key":"3068_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-58290-8","volume":"16","author":"EJ Lee","year":"2025","unstructured":"Lee EJ, Kim M, Park S, Shim JH, Cho HJ, Park JA, et al. Restoration of retinal regenerative potential of m\u00fcller glia by disrupting intercellular Prox1 transfer. Nat Commun. 2025;16:2928.","journal-title":"Nat Commun"},{"key":"3068_CR17","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.jcmgh.2016.09.002","volume":"2","author":"M Tanaka","year":"2016","unstructured":"Tanaka M, Iwakiri Y. The hepatic lymphatic vascular system: Structure, function, markers, and lymphangiogenesis. Cell Mol Gastroenterol Hepatol. 2016;2:733\u201349.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"3068_CR18","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.3390\/diagnostics12071624","volume":"12","author":"E Ntikoudi","year":"2022","unstructured":"Ntikoudi E, Pergaris A, Kykalos S, Politi E, Theocharis S. The role of PROX1 in neoplasia: A key player often overlooked. Diagnostics. 2022;12:1624.","journal-title":"Diagnostics"},{"key":"3068_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49063-w","volume":"15","author":"M Sasaki","year":"2024","unstructured":"Sasaki M, Kato D, Murakami K, Yoshida H, Takase S, Otsubo T, et al. Targeting dependency on a paralog pair of CBP\/p300 against de-repression of KREMEN2 in SMARCB1-deficient cancers. Nat Commun. 2024;15:4770.","journal-title":"Nat Commun"},{"key":"3068_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14648","volume":"8","author":"BH Alver","year":"2017","unstructured":"Alver BH, Kim KH, Lu P, Wang X, Manchester HE, Wang W, et al. The SWI\/SNF chromatin remodelling complex is required for maintenance of lineage specific enhancers. Nat Commun. 2017;8:14648.","journal-title":"Nat Commun"},{"key":"3068_CR21","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/s41556-021-00743-5","volume":"23","author":"A Davies","year":"2021","unstructured":"Davies A, Nouruzi S, Ganguli D, Namekawa T, Thaper D, Linder S, et al. An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer. Nat Cell Biol. 2021;23:1023\u201334.","journal-title":"Nat Cell Biol"},{"key":"3068_CR22","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1158\/0008-5472.CAN-17-3677","volume":"78","author":"X Ci","year":"2018","unstructured":"Ci X, Hao J, Dong X, Choi SY, Xue H, Wu R, et al. Heterochromatin protein 1\u03b1 mediates development and aggressiveness of neuroendocrine prostate cancer. Cancer Res. 2018;78:2691\u2013704.","journal-title":"Cancer Res"},{"key":"3068_CR23","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2322203121","volume":"121","author":"S Zaidi","year":"2024","unstructured":"Zaidi S, Park J, Chan JM, Roudier MP, Zhao JL, Gopalan A, et al. Single-cell analysis of treatment-resistant prostate cancer: Implications of cell state changes for cell surface antigen-targeted therapies. Proc Natl Acad Sci USA. 2024;121:e2322203121.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3068_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00667-x","volume":"8","author":"S Cheng","year":"2024","unstructured":"Cheng S, Li L, Yeh Y, Shi Y, Franco O, Corey E, et al. Unveiling novel double-negative prostate cancer subtypes through single-cell RNA sequencing analysis. NPJ Precis Oncol. 2024;8:171.","journal-title":"NPJ Precis Oncol"},{"key":"3068_CR25","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s10555-013-9471-3","volume":"33","author":"MA Augello","year":"2014","unstructured":"Augello MA, Den RB, Knudsen KE. AR function in promoting metastatic prostate cancer. Cancer Metastasis Rev. 2014;33:399\u2013411.","journal-title":"Cancer Metastasis Rev"},{"key":"3068_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32701-6","volume":"13","author":"TC Westbrook","year":"2022","unstructured":"Westbrook TC, Guan X, Rodansky E, Flores D, Liu CJ, Udager AM, et al. Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity. Nat Commun. 2022;13:5345.","journal-title":"Nat Commun"},{"key":"3068_CR27","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1200\/JCO.2017.77.6880","volume":"36","author":"R Aggarwal","year":"2018","unstructured":"Aggarwal R, Huang J, Alumkal JJ, Zhang L, Feng FY, Thomas GV, et al. Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: A multi-institutional prospective study. J Clin Oncol J Am Soc Clin Oncol. 2018;36:2492\u2013503.","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"key":"3068_CR28","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1038\/s41588-025-02265-4","volume":"57","author":"X Lu","year":"2025","unstructured":"Lu X, Keo V, Cheng I, Xie W, Gritsina G, Wang J, et al. NKX2-1 drives neuroendocrine transdifferentiation of prostate cancer via epigenetic and 3D chromatin remodeling. Nat Genet. 2025;57:1966\u201380.","journal-title":"Nat Genet"},{"key":"3068_CR29","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1158\/2159-8290.CD-21-0576","volume":"12","author":"S Linder","year":"2022","unstructured":"Linder S, Hoogstraat M, Stelloo S, Eickhoff N, Schuurman K, de Barros H, et al. Drug-induced epigenomic plasticity reprograms circadian rhythm regulation to drive prostate cancer toward androgen independence. Cancer Discov. 2022;12:2074\u201397.","journal-title":"Cancer Discov"},{"key":"3068_CR30","first-page":"144","volume":"43","author":"N Jing","year":"2024","unstructured":"Jing N, Du X, Liang Y, Tao Z, Bao S, Xiao H, et al. PAX6 promotes neuroendocrine phenotypes of prostate cancer via enhancing MET\/STAT5A-mediated chromatin accessibility. J Exp Clin Cancer Res CR. 2024;43:144.","journal-title":"J Exp Clin Cancer Res CR"},{"key":"3068_CR31","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1038\/s41418-024-01295-5","volume":"31","author":"D Wang","year":"2024","unstructured":"Wang D, Du G, Chen X, Wang J, Liu K, Zhao H, et al. Zeb1-controlled metabolic plasticity enables remodeling of chromatin accessibility in the development of neuroendocrine prostate cancer. Cell Death Differ. 2024;31:779\u201391.","journal-title":"Cell Death Differ"},{"key":"3068_CR32","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13045-024-01572-3","volume":"17","author":"E Redin","year":"2024","unstructured":"Redin E, Sridhar H, Zhan YA, Pereira Mello B, Zhong H, Durani V, et al. SMARCA4 controls state plasticity in small cell lung cancer through regulation of neuroendocrine transcription factors and REST splicing. J Hematol Oncol J Hematol Oncol. 2024;17:58.","journal-title":"J Hematol Oncol J Hematol Oncol"},{"key":"3068_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1290717","volume":"13","author":"P Zhou","year":"2023","unstructured":"Zhou P, Fu Y, Wang W. Case report: Gastrointestinal neuroendocrine carcinoma with SMARCA4 deficiency: a clinicopathological report of two rare cases. Front Oncol. 2023;13:1290717.","journal-title":"Front Oncol"},{"key":"3068_CR34","doi-asserted-by":"publisher","first-page":"5901","DOI":"10.1158\/0008-5472.CAN-18-0320","volume":"78","author":"KM Goudarzi","year":"2018","unstructured":"Goudarzi KM, Espinoza JA, Guo M, Bartek J, Nist\u00e9r M, Lindstr\u00f6m MS, et al. Reduced expression of PROX1 transitions glioblastoma cells into a mesenchymal gene expression subtype. Cancer Res. 2018;78:5901\u201316.","journal-title":"Cancer Res"},{"key":"3068_CR35","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41586-024-08150-0","volume":"637","author":"A Moorman","year":"2025","unstructured":"Moorman A, Benitez EK, Cambulli F, Jiang Q, Mahmoud A, Lumish M, et al. Progressive plasticity during colorectal cancer metastasis. Nature. 2025;637:947\u201354.","journal-title":"Nature"},{"key":"3068_CR36","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/s41417-024-00732-4","volume":"31","author":"X Li","year":"2024","unstructured":"Li X, Tian S, Shi H, Ta N, Ni X, Bai C, et al. The golden key to open mystery boxes of SMARCA4-deficient undifferentiated thoracic tumor: Focusing immunotherapy, tumor microenvironment and epigenetic regulation. Cancer Gene Ther. 2024;31:687\u201397.","journal-title":"Cancer Gene Ther"}],"container-title":["Cell Death Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41420-026-03068-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-026-03068-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-026-03068-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T19:22:26Z","timestamp":1774984946000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41420-026-03068-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3068"],"URL":"https:\/\/doi.org\/10.1038\/s41420-026-03068-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8272309\/v1","asserted-by":"object"}]},"ISSN":["2058-7716"],"issn-type":[{"value":"2058-7716","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"assertion":[{"value":"3 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The experimental protocol was approved by the Institutional Animal Care and Use Committee of Ruipu Model Animal Biotechnology Co., Ltd. (Guangzhou, China) (Approval No. RYEth-20250901936). All animal experiments were performed in strict accordance with the guidelines of the Guide for the Care and Use of Laboratory Animals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"175"}}